News Center

With the tenet of "Healthy China, Dedicated commitment", Linuo Pharmaceuticals increases cooperation and association with external scientific research institutes while innovating and developing independently.

Corporate News

Staff Style

Home page

The Chairman of Keyuan Pharmaceutical was invited to attend the Third Global Go‑Global Summit, where they jointly explored new pathways for the pharmaceutical industry’s international expansion.

2026

Linuo Pharmaceutical unveils its 2026 Starry Night Summit, with a glorious coronation that underscores its formidable strength!

2026

Deep Affection on the Dragon Boat Festival, Zongzi Aroma Fills the Courtyard | Linuo Pharmaceutical Warmly Hosts a Special Dragon Boat Festival Event

2026

Renowned financial writer Wu Xiaobo visited Keyuan Pharmaceutical, praising the company’s achievements in digital and intelligent transformation.

On May 16–17, Wu Xiaobo, known as “China’s foremost financial writer” and a renowned entrepreneur, led a delegation to visit and inspect Keyuan Pharmaceutical (stock code: 301281.SZ). The group focused on the company’s achievements in integrating smart manufacturing with digital AI technologies in the pharmaceutical sector, engaged in in-depth discussions with its core management team, and expressed high praise for the company’s practical approach to driving industrial upgrading through digital and intelligent transformation. Gao Yuankun, Chairman and President of Linuo Group, along with Li Hongfu, Chairman of Keyuan Pharmaceutical, and Wei Zhiguo, President of the company, accompanied the delegation during the visit.

2026

Dual Exhibitions, Full-Chain Collaboration | Keyuan Pharmaceutical, together with its subsidiary Linuo Pharmaceutical, proudly showcases its offerings at the Shanghai International Pharmaceutical Dual Exhibitions!

On May 13, the 92nd National Pharmaceutical Fair and the 94th China International API, Intermediate, Packaging & Equipment Exhibition (API China) opened in grand style at the Shanghai National Exhibition and Convention Center. As an innovative, publicly listed company in China’s chemical pharmaceutical sector, Shandong Keyuan Pharmaceutical Co., Ltd. (301281.SZ), together with its wholly owned subsidiary Shandong Linuo Pharmaceutical Co., Ltd., made a high‑profile appearance, showcasing a coordinated approach to APIs and finished dosage forms, a comprehensive end-to-end product portfolio, and strong brand synergy. The company highlighted its robust capabilities in innovative R&D, digital and intelligent manufacturing, green production, global supply chains, and clinical translation, while engaging domestic and international partners to explore emerging industry trends, expand new avenues of collaboration, and co‑create a thriving new ecosystem for the pharmaceutical and healthcare sectors.

2026

Guided by the principle of “the entire organization as one cohesive unit, with the entire camp operating under a single command,” Keyuan Pharmaceutical’s subsidiary ushers in a new chapter in strategic implementation.

On May 6, Lino Pharmaceutical, a subsidiary of Keyuan Pharmaceutical (stock code: 301281.SZ), held a company-wide meeting in Jinan. Centered on the core principle of “unified strategy across the entire workforce and coordinated action across all business units,” the meeting comprehensively communicated the company’s development strategy and outlined the implementation roadmap, aligning the thinking and building consensus among all employees. With a spirit of concerted effort and synchronized momentum, the meeting charted a new blueprint for the company’s high-quality development.

2026

< 1 2 3 4...25 >

TEL：+86-531-88729642

E-mail：lnyybgs@lnphar.com

ADD：#30766 Jingshidong Road, Linuo High-tech Park, Jinan, Shandong Province, P. R. China